E-MAIL: [email protected]
FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
132024.08
Child-resistant packaging certification and ISO 8317 standard analysis
122024.08
FDA Approves First Nasal Spray for Treatment of Anaphylaxis
092024.08
USP〈1711〉 ORAL DOSAGE FORMS - PERFORMANCE TESTS
Copyright © Shijiazhuang Xinfuda Medical Packaging Co., Ltd. All Rights
Reserved Powered by
MAKE AN ENQUIRY